Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
Bacterial vaginosis and other vaginal health conditions remain prevelant and can negatively impact a woman’s quality of life, become an economic burden, and more. Scientific evidence suggests that there may be potential benefits to administering live bacterial cultures to rebalance the vaginal microbiota disrupted by the infection.
On December 7, 2021, Daré Bioscience announced its FDA approval of the company’s clindamycin phosphate vaginal gel, 2% for the treatment of bacterial vaginosis in females 12 years of age and older. On June 30, 2022, Daré announced its exclusive license agreement with Organon.
“One of Daré’s top priorities is to accelerate the development of differentiated products that can not only improve outcomes but increase access and convenience for women,” said David Friend, PhD, chief scientific officer of Daré Bioscience. “We previously demonstrated the ability of a novel hydrogel technology to effectively deliver an active pharmaceutical ingredient vaginally through the development and approval of clindamycin phosphate vaginal gel, 2% (XACIATO™), our FDA-approved treatment for bacterial vaginosis in females 12 years of age and older for which global commercialization rights have been licensed to Organon. However, there remains a clear and unmet need for products that can be administered following effective treatment of the primary vaginal infection to then rebalance the vaginal microbiota and promote continued improved vaginal health. This grant will enable us to investigate the use of a novel hydrogel technology to deliver live biotherapeutics to address this challenge that affects women everywhere. We are grateful for the foundation’s support in advancing this technology with the goal of making such therapies available to women worldwide.”
1. Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health | Daré Bioscience. Daré Bioscience. Published 2022. Accessed November 16, 2022. https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-grant-develop-novel-hydrogel